Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis

Figures & data

Table 1 Primary and secondary endpoints of the ADVANCE trial

	First year			Second year
	PEG-IFN 2 weeks	PEG-IFN 4 weeks	Placebo	PEG-IFN 2 weeks	PEG-IFN 4 weeks	Delayed PEG-IFN
Total number	512	500	500	512	500	500
Annualized relapse rate (95% CI)	0.256 (0.206–0.318)	0.288 (0.234–0.355)	0.397 (0.328–0.481)	0.221 (0.183–0.267)	0.291 (0.244–0.348)	0.35 (0.295–0.418)
Proportion of patients with a relapse
Number	90	105	142	124	158	192
Proportion	0.187	0.222	0.291	0.265	0.344	0.402
Disability progression (12 weeks confirmed)
Number	31	31	50	51	56	75
Proportion	0.068	0.068	0.105	0.112	0.123	0.162
New or newly enlarging T2 lesion
Number of patients evaluated	457	462	476	407	389	393
Adjusted mean lesion number	3.6	7.9	10.9	5.0	12.5	14.8

Notes: Results for the first³¹ and second year³² are presented. Reprinted from Lancet Neurol, 13, Calabresi PA, Kieseier BC, Arnold DL, et al. ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, Phase 3, double-blind study. 657–665., Copyright (2014), with permission from Elsevier.³¹ Reprinted from Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. Copyright ^© 2014. Reprinted by Permission of SAGE.³²

Abbreviations: CI, confidence interval; PEG-IFN, polyethylene glycol (PEG)ylated interferon.

CalabresiPAKieseierBCArnoldDLADVANCE Study InvestigatorsPegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, Phase 3, double-blind studyLancet Neurol20141365766524794721

 PubMed Web of Science ®Google Scholar

KieseierBCArnoldDLBalcerLJPeginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCEMult Scler11282014 Epub ahead of print

 Google Scholar